New study compares promising drug to standard care for multiple HER2-Positive cancers
NCT ID NCT06973161
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 36 times
Summary
This study looked at how well the drug T-DXd works compared to standard treatments for people with several types of HER2-positive cancers that have spread. Researchers used data from past trials and real-world patient records to compare survival. The goal was to see if T-DXd offers a better chance of living longer for these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Spartanburg, South Carolina, 29303, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Vienna, Austria
-
Research Site
Liège, Belgium
-
Research Site
London, Ontario, N6A 5A5, Canada
-
Research Site
Olomouc, Czechia
-
Research Site
Copenhagen, Denmark
-
Research Site
Caen, France
-
Research Site
Lille, France
-
Research Site
Marseille, France
-
Research Site
Nice, France
-
Research Site
Paris, France
-
Research Site
Saint-Herblain, France
-
Research Site
Berlin, Germany
-
Research Site
Essen, Germany
-
Research Site
Frankfurt, Germany
-
Research Site
Heidelberg, Germany
-
Research Site
Würzburg, Germany
-
Research Site
Meldola, Italy
-
Research Site
Rome, Italy
-
Research Site
Porto, Portugal
-
Research Site
Barcelona, Spain
-
Research Site
Madrid, Spain
-
Research Site
Pamplona, Spain
-
Research Site
Valencia, Spain
-
Research Site
Leeds, United Kingdom
-
Research Site
London, United Kingdom
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.